DPX-SurMAGE / BioVaxys - LARVOL DELTA

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE (PRNewswire) - "BioVaxys Technology Corp...announced that it has received a Notice of Allowance from the United States Patent and Trademark Office ('USPTO') for a Patent ('Patent') for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX. Part of the extensive Intellectual Property portfolio acquired by BioVaxys from the former IMV, Inc, this Patent was recently allowed in Japan and is currently pending in the European Union....BioVaxys also is pleased to announce it has entered the national phase in the United States, Canada, European Union, Japan, and Australia with its patent application for DPX-survivin/MAGE A9 (DPX SurMAGE), a DPX formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. "

Patent • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC. (Canada Newswire) - "ioVaxys Technology Corp...is pleased to announce has completed the acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets of former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA ('IMV'). On February 11th, 2024, the Company executed the definitive Asset Purchase Agreement for the extensive technology portfolio from HIMV, LLC, an acquisition vehicle formed by Horizon Technology Finance Corporation...and IMV's other secured creditors for the purpose of acquiring IMV's intellectual property through a secured party credit bid in the proceedings commenced in Canada by IMV under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended (the 'CCAA')....Prior clinical studies by IMV have supported proof of concept...DPX-packaged survivin/MAGE-Ag for advanced metastatic bladder cancer, and certain other infectious diseases."

M&A • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results (Businesswire) - "Expected Upcoming Clinical Milestones - Q2 2023: Stage 1 enrollment complete for the Phase 2B VITALIZE r/r DLBCL trial (30 patients); Q3 2023: Stage 1 enrollment complete for the Phase 2B AVALON platinum-resistant ovarian cancer trial (approximately 40 patients); Q3 2023: Preliminary Phase 1 data from the MVP-S and DPX-SurMAGE in non-muscle invasive bladder cancer (NMIBC)."

Enrollment status • P1 data • Bladder Cancer • Diffuse Large B Cell Lymphoma • Genito-urinary Cancer • Gynecologic Cancers • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer

"Yves Fradet shows results of DPX-SurMAGE, a novel dual-targeted immunotherapy, on bladder cancer #urs22 @MaxKates @ViFradet @DrDeanElterman @pcvblack" (@cgratzke)

Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results (Businesswire) - “April 2022: Present detailed top line data on the bladder cancer cohort from the basket trial at a late-breaking oral presentation at the annual AACR meeting. H2 2022: Initiate enrollment in AVALON open-label Phase 2B Avalon platinum-resistant ovarian cancer trial. December 2022: Present first clinical and translational results update for the investigator-initiated breast cancer trial. Q4 2022: Present preliminary Phase 1 data from the MVP-S and DPX-SurMAGE in non-muscle invasive bladder cancer (NMIBC).”

Late-breaking abstract • P1 data • Trial status • Bladder Cancer • Breast Cancer • Genito-urinary Cancer • Gynecologic Cancers • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • Urothelial Cancer

"Also targeting #MAGEA9 with #DPX-SurMAGE!" (@kmody29)

IMV Inc. Announces Third Quarter 2021 Financial and Operational Update (Businesswire) - "Selected Upcoming Milestones: DPX-SurMAGE: (i) H2 2021: Initiation of a Phase 1 clinical study in bladder cancer at year-end."

New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer